The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells

Cancer Immunology, Immunotherapy

Volumn 59, Issue 1, 2010, Pages 35-46

  Smits, Evelien L J M ^a   Cools, Nathalie ^a   Lion, Eva ^a   Van Camp, Kirsten ^a   Ponsaerts, Peter ^a   Berneman, Zwi N ^a,b   Van Tendeloo, Viggo F I ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

AML; Immunotherapy; R 848; TLR7; TLR8

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ELECTROPORATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; LEUKEMIA CELL; MALE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CELL SURVIVAL; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 70350116951     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0721-8     Document Type: Article

References (59)

1. V Hornung S Rothenfusser S Britsch, et al. 2002 Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides J Immunol 168 4531 4537 11970999 1:CAS:528:DC%2BD38Xjt12jt7k%3D
2. KA Zarember PJ Godowski 2002 Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines J Immunol 168 554 561 11777946 1:CAS:528:DC%2BD38XksFWntg%3D%3D
3. S Akira S Uematsu O Takeuchi 2006 Pathogen recognition and innate immunity Cell 124 783 801 10.1016/j.cell.2006.02.015 16497588 1:CAS:528:DC%2BD28Xit1Kltb8%3D (Pubitemid 43261452)
4. M Jurk F Heil J Vollmer, et al. 2002 Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 Nat Immunol 3 499 10.1038/ni0602-499 12032557 1:CAS:528:DC%2BD38XjvFOmsLo%3D (Pubitemid 34669818)
5. MP Schon M Schon 2008 TLR7 and TLR8 as targets in cancer therapy Oncogene 27 190 199 10.1038/sj.onc.1210913 18176600 1:CAS:528:DC%2BD1cXitl2iuw%3D%3D
6. TL Wagner CL Ahonen AM Couture, et al. 1999 Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod Cell Immunol 191 10 19 10.1006/cimm.1998.1406 9918682 1:CAS:528:DyaK1MXpvF2quw%3D%3D (Pubitemid 29054962)
7. SJ Gibson JM Lindh TR Riter, et al. 2002 Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod Cell Immunol 218 74 86 10.1016/S0008-8749(02)00517-8 12470615 1:CAS:528:DC%2BD38XpsF2ksbc%3D (Pubitemid 36027092)
8. G Stary C Bangert M Tauber, et al. 2007 Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells J Exp Med 204 1441 1451 10.1084/jem.20070021 17535975 1:CAS:528:DC%2BD2sXms1aktLo%3D (Pubitemid 46919881)
9. TL Wagner VL Horton GL Carlson, et al. 1997 Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463 Cytokine 9 837 845 10.1006/cyto.1997.0239 9367544 1:CAS:528: DyaK2sXnslChs7c%3D (Pubitemid 27494148)
10. JP Vasilakos RM Smith SJ Gibson, et al. 2000 Adjuvant activities of immune response modifier R-848: comparison with CpG ODN Cell Immunol 204 64 74 10.1006/cimm.2000.1689 11006019 1:CAS:528:DC%2BD3cXmslKnsr4%3D (Pubitemid 30766301)
11. MA Tomai LM Imbertson TL Stanczak, et al. 2000 The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes Cell Immunol 203 55 65 10.1006/cimm.2000.1673 10915562 1:CAS:528:DC%2BD3cXltFenu78%3D (Pubitemid 30627030)
12. M Otero SA Calarota B Felber, et al. 2004 Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model Vaccine 22 1782 1790 10.1016/j.vaccine.2004.01.037 15068862 1:CAS:528:DC%2BD2cXivVGjsL8%3D (Pubitemid 38455417)
13. LL Thomsen P Topley MG Daly, et al. 2004 Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery Vaccine 22 1799 1809 10.1016/j.vaccine.2003.09.052 15068864 1:CAS:528:DC%2BD2cXivVGjsL0%3D (Pubitemid 38447228)
14. EL Smits P Ponsaerts ZN Berneman, et al. 2008 The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy Oncologist 13 859 875 10.1634/theoncologist.2008-0097 18701762 1:CAS:528:DC%2BD1cXhtF2qs7vL
15. DN Sauder MH Smith T Senta-McMillian, et al. 2003 Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults Antimicrob Agents Chemother 47 3846 3852 10.1128/AAC.47.12.3846-3852.2003 14638493 1:CAS:528: DC%2BD3sXpsV2nuro%3D (Pubitemid 37484999)
16. M Sioud Y Floisand 2007 TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response Eur J Immunol 37 2834 2846 10.1002/eji.200737112 17853407 1:CAS:528:DC%2BD2sXht1ersrvM (Pubitemid 47578303)
17. J Bohnhorst T Rasmussen SH Moen, et al. 2006 Toll-like receptors mediate proliferation and survival of multiple myeloma cells Leukemia 20 1138 1144 10.1038/sj.leu.2404225 16617319 1:CAS:528:DC%2BD28XkvVymu7w%3D (Pubitemid 43797309)
18. DE Spaner A Masellis 2007 Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia Leukemia 21 53 60 10.1038/sj.leu.2404456 17066089 1:CAS:528:DC%2BD28XhtlSqur3F (Pubitemid 44921834)
19. G Jego R Bataille A Geffroy-Luseau, et al. 2006 Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors Leukemia 20 1130 1137 10.1038/sj.leu.2404226 16628189 1:CAS:528:DC%2BD28XkvVymu70%3D (Pubitemid 43797308)
20. A Pellacani P Tosi PL Zinzani, et al. 1999 Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells Leuk Lymphoma 33 147 153 10194132 1:STN:280:DyaK1M3gvVCktw%3D%3D (Pubitemid 29116405)
21. DE Spaner Y Shi D White, et al. 2006 Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells Leukemia 20 286 295 10.1038/sj.leu.2404061 16341037 1:CAS:528:DC%2BD28XmvVSjsQ%3D%3D (Pubitemid 43148667)
22. EL Smits P Ponsaerts AL Van de Velde, et al. 2007 Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells Leukemia 21 1691 1699 10.1038/sj.leu.2404763 17525722 1:CAS:528:DC%2BD2sXnvVelur8%3D (Pubitemid 47086759)
23. P Ponsaerts VF Van Tendeloo N Cools, et al. 2002 mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation Leukemia 16 1324 1330 10.1038/sj.leu.2402511 12094257 1:CAS:528:DC%2BD38XkvFKrsbs%3D (Pubitemid 34893572)
24. K Fischer R Andreesen A Mackensen 2002 An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity J Immunol Methods 259 159 169 10.1016/S0022-1759(01)00507-5 11730851 1:CAS:528:DC%2BD3MXos1ansL0%3D (Pubitemid 33124393)
25. G Caron D Duluc I Fremaux, et al. 2005 Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells J Immunol 175 1551 1557 16034093 1:CAS:528:DC%2BD2MXmtlWjt7k%3D
26. M Nishimura S Naito 2005 Tissue-specific mRNA expression profiles of human toll-like receptors and related genes Biol Pharm Bull 28 886 892 10.1248/bpb.28.886 15863899 1:CAS:528:DC%2BD2MXlvVWitL0%3D (Pubitemid 40740661)
27. A Iwasaki R Medzhitov 2004 Toll-like receptor control of the adaptive immune responses Nat Immunol 5 987 995 10.1038/ni1112 15454922 1:CAS:528:DC%2BD2cXnvFCgsrg%3D (Pubitemid 41057715)
28. A Mazzoni DM Segal 2004 Controlling the Toll road to dendritic cell polarization J Leukoc Biol 75 721 730 10.1189/jlb.1003482 14726500 1:CAS:528:DC%2BD2cXjvVakurk%3D (Pubitemid 38580050)
29. SL Corthals K Wynne K She, et al. 2006 Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia Br J Haematol 132 452 458 16412017 1:CAS:528: DC%2BD28XislCqu70%3D
30. CI Maratheftis S Giannouli MP Spachidou, et al. 2007 RNA interference of interferon regulatory factor-1 gene expression in THP-1 cell line leads to Toll-like receptor-4 overexpression/activation as well as up-modulation of annexin-II Neoplasia 9 1012 1020 10.1593/neo.07640 18084608 1:CAS:528: DC%2BD1cXltleju7o%3D (Pubitemid 350255348)
31. CI Maratheftis E Andreakos HM Moutsopoulos, et al. 2007 Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes Clin Cancer Res 13 1154 1160 10.1158/1078-0432.CCR-06-2108 17317824 1:CAS:528:DC%2BD2sXhvF2hsLY%3D (Pubitemid 46424055)
32. RP Burns Jr B Ferbel M Tomai, et al. 2000 The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells Clin Immunol 94 13 23 10.1006/clim.1999.4804 10607486 1:CAS:528:DC%2BD3cXos1yrtg%3D%3D (Pubitemid 30026907)
33. DI Bernstein CJ Harrison MA Tomai, et al. 2001 Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment J Infect Dis 183 844 849 10.1086/319262 11237799 1:CAS:528:DC%2BD3MXisV2kur4%3D (Pubitemid 32207051)
34. M Schon AB Bong C Drewniok, et al. 2003 Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod J Natl Cancer Inst 95 1138 1149 12902443
35. R Sun Z Tian S Kulkarni, et al. 2004 IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners J Immunol 172 5648 5655 15100309 1:CAS:528:DC%2BD2cXjt1Cktbo%3D
36. DL Vredevoe M Widawski GC Fonarow, et al. 2004 Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure Am J Cardiol 93 1007 1011 10.1016/j.amjcard.2003.12.054 15081444 1:CAS:528:DC%2BD2cXjtVemsrk%3D (Pubitemid 38479455)
37. B Huang J Zhao H Li, et al. 2005 Toll-like receptors on tumor cells facilitate evasion of immune surveillance Cancer Res 65 5009 5014 10.1158/0008-5472.CAN-05-0784 15958541 1:CAS:528:DC%2BD2MXltFemtLo%3D (Pubitemid 40827306)
38. DR Averett SP Fletcher W Li, et al. 2007 The pharmacology of endosomal TLR agonists in viral disease Biochem Soc Trans 35 1468 1472 10.1042/BST0351468 18031247 1:CAS:528:DC%2BD2sXhtlGmtL3O
39. SS Diebold T Kaisho H Hemmi, et al. 2004 Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA Science 303 1529 1531 10.1126/science.1093616 14976261 1:CAS:528:DC%2BD2cXhslCgsb4%3D (Pubitemid 38314425)
40. K Kariko M Buckstein H Ni, et al. 2005 Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA Immunity 23 165 175 10.1016/j.immuni.2005.06.008 16111635 1:CAS:528:DC%2BD2MXpvVCnu74%3D (Pubitemid 41169286)
41. YC Linn KM Hui 2003 Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia Leuk Lymphoma 44 1457 1462 10.1080/1042819031000083082 14565644 1:CAS:528:DC%2BD3sXmtFalsr8%3D (Pubitemid 36833956)
42. JR Passweg A Tichelli S Meyer-Monard, et al. 2004 Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation Leukemia 18 1835 1838 10.1038/sj.leu.2403524 15457184 1:STN:280:DC%2BD2crjsVartA%3D%3D (Pubitemid 39530014)
43. J Tanaka M Asaka M Imamura 2005 Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia Int J Hematol 81 6 12 10.1532/IJH97.04152 15717681 1:CAS:528:DC%2BD2MXhvFGmsb8%3D (Pubitemid 40165416)
44. L Ruggeri A Mancusi K Perruccio 2005 Natural killer cell alloreactivity for leukemia therapy J Immunother 28 175 182 10.1097/01.cji.0000161395.88959.1f 15838373 1:CAS:528:DC%2BD2MXjtlKlur0%3D
45. K Seino S Motohashi T Fujisawa, et al. 2006 Natural killer T cell-mediated antitumor immune responses and their clinical applications Cancer Sci 97 807 812 10.1111/j.1349-7006.2006.00257.x 16805854 1:CAS:528: DC%2BD28XpsFels7s%3D (Pubitemid 44151258)
46. P Kalinski A Giermasz Y Nakamura, et al. 2005 Helper role of NK cells during the induction of anticancer responses by dendritic cells Mol Immunol 42 535 539 10.1016/j.molimm.2004.07.038 15607810 1:CAS:528:DC%2BD2cXhtVyktrnL (Pubitemid 39655965)
47. L Ruggeri A Mancusi E Burchielli, et al. 2006 Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation Cytotherapy 8 554 558 10.1080/14653240601078721 17148031 1:CAS:528:DC%2BD2sXit1aqur4%3D (Pubitemid 44869855)
48. L Moretta F Locatelli A Moretta 2008 Alloreactive natural killer cells in targeting high-risk leukaemias Ann Rheum Dis 67 Suppl 3 iii39 iii43 10.1136/ard.2008.097980 19022812
49. RT Costello C Fauriat J Rey, et al. 2004 Immunobiology of haematological malignant disorders: the basis for novel immunotherapy protocols Lancet Oncol 5 47 55 10.1016/S1470-2045(03)01323-8 14700608 1:CAS:528:DC%2BD3sXhtVWjtrbM (Pubitemid 38072559)
50. OM Hart V Athie-Morales GM O'Connor, et al. 2005 TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production J Immunol 175 1636 1642 16034103 1:CAS:528:DC%2BD2MXmtlWjtLk%3D
51. KS Gorski EL Waller J Bjornton-Severson, et al. 2006 Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists Int Immunol 18 1115 1126 10.1093/intimm/dxl046 16728430 1:CAS:528:DC%2BD28XmtFKgtrY%3D (Pubitemid 43923429)
52. J Sawaki H Tsutsui N Hayashi, et al. 2007 Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways Int Immunol 19 311 320 10.1093/intimm/dxl148 17289654 1:CAS:528:DC%2BD2sXitFyjsrw%3D (Pubitemid 46344696)
53. G Alter TJ Suscovich N Teigen, et al. 2007 Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells J Immunol 178 7658 7666 17548602 1:CAS:528:DC%2BD2sXmtVKgurg%3D
54. MV Girart MB Fuertes CI Domaica, et al. 2007 Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12 J Immunol 179 3472 3479 17804388 1:CAS:528:DC%2BD2sXpvFKmu7k%3D
55. MA Degli-Esposti MJ Smyth 2005 Close encounters of different kinds: dendritic cells and NK cells take centre stage Nat Rev Immunol 5 112 124 10.1038/nri1549 15688039 1:CAS:528:DC%2BD2MXovFKnsg%3D%3D (Pubitemid 40208901)
56. R Biassoni 2008 Natural killer cell receptors Adv Exp Med Biol 640 35 52 10.1007/978-0-387-09789-3-4 19065782
57. S Verheyden C Demanet 2008 NK cell receptors and their ligands in leukemia Leukemia 22 249 257 10.1038/sj.leu.2405040 18046448 1:CAS:528:DC%2BD1cXhvVyltLo%3D (Pubitemid 351250528)
58. K Ogasawara LL Lanier 2005 NKG2D in NK and T cell-mediated immunity J Clin Immunol 25 534 540 10.1007/s10875-005-8786-4 16380817 1:CAS:528: DC%2BD2MXhtlGhsbzN (Pubitemid 43011745)
59. A Moretta C Bottino M Vitale, et al. 2001 Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis Annu Rev Immunol 19 197 223 10.1146/annurev.immunol.19.1.197 11244035 1:CAS:528:DC%2BD3MXivFKgtbk%3D (Pubitemid 32368034)